A Phase 1 interventional study of LY4298445 and LY4298445 in Healthy, Systemic Lupus Erythematosus and Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Recruiting at 10 sites in 3 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Lupus Erythematosus, Systemic · Eli Lilly and Company.
Among the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 2 in phase 1, and was the 11th registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →1 of the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company is open now, in 3 countries.
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 68 is above the median of 52 across 879 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 778 across the 11 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Lupus Erythematosus, Systemic by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks.
Inclusion Criteria: Healthy Participants
Healthy participants between the ages of 18 and 55 years.
Participants with Systemic Lupus Erythematosus (SLE)
Participants with Rheumatoid Arthritis (RA)
Exclusion Criteria:
Have severe active lupus-associated renal disease (lupus nephritis) defined clinically and/or by
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-ascending dose (SAD) of LY4298445 administered subcutaneously (SC) or intravenously (IV) in healthy participants
Drug: LY4298445
SAD of LY4298445 administered SC or IV in healthy participants
Drug: LY4298445
SAD of LY4298445 administered SC in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)
Drug: LY4298445
Multiple-ascending doses (MAD) of LY4298445 administered SC in participants with SLE or RA
Drug: LY4298445
Single dose of LY4298445 administered SC in healthy Japanese and, optionally, Chinese participants
Drug: LY4298445
Single dose of LY4298445 administered SC in healthy Japanese and, optionally, Chinese participants
Drug: LY4298445
Administered SC
Administered IV
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline up to Week 52
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY4298445
PK: AUC of LY4298445
Time frame: Baseline up to Approximately Week 57
PK: Maximum Concentration (Cmax) of LY4298445
PK: Cmax of LY4298445
Time frame: Baseline up to Week 52
Pharmacodynamic (PD): Degree of Peripheral B Cell Depletion Following Biopsy in Participants
PD: Peripheral B cell depletion
Time frame: Baseline up to Week 52
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.
Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 25 months is below that.
Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic →